- Paper Report
- Open Access
Response to CMF according to HER-2 overexpression
- Richard de Boer1
© Biomed Central Ltd 2001
- Received: 9 April 2001
- Accepted: 20 August 2001
- Published: 1 December 2001
- CMF, HER-2, node positive
A major aim of current research in breast cancer is more effective targeting of chemotherapy. Biological markers may provide one way of identifying patients more or less likely to respond to a particular therapy/regimen. HER-2 overexpression appears to be a potential indicator of responsiveness to doxorubicin and paclitaxel, and conversely of unresponsiveness to tamoxifen. It has been suggested that HER-2 overexpression may result in a decrease in responsiveness to cyclophosphamide, methotrexate, and fluorouracil (CMF). This study examined HER-2 overexpression and clinical benefit in the 386 node-positive breast cancer patients in the first trial of CMF versus no treatment with a 20-year follow-up.
Overexpression was found to be inversely associated with oestrogen receptor (ER) and progesterone receptor (PgR) expression. Results showed a clinical benefit from CMF treatment irrespective of the HER-2 expression levels within the tumour. There was no evidence to suggest an inversion of treatment effect in patients with HER-2-overexpressing tumours. The authors concluded that patients with either HER-2-positive or HER-2-negative tumours obtained benefit from CMF treatment, and the poor prognosis associated with the HER-2 overexpression in the untreated group could be overcome by administration of CMF.
Randomised clinical trial, retrospective analysis, immunohistochemistry, Bayesian subset analysis
Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM: Effect of c-erbB2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999, 84:354-359 (PubMed%20abstract).
- Menard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumour biologic variables. J Clin Oncol . 2001, 19: 329-335.PubMedGoogle Scholar